The activity of NXL101 against fluoroquinolone-resistant clinical isolates of Staphylococcus aureus
Abstract number: 1732_299
Morrissey I., Lowther J., Soltani M., Northwood J.
Objectives: To evaluate the novel topoisomerase inhibitor NXL101 against fluoroquinolone-resistant (FQR) S. aureus (SA).
Methods: MIC against 39 FQR SA and the control strain ATCC29213 (Cont) was determined for NXL101, levofloxacin (LFX), ciprofloxacin (CFX), moxifloxacin (MFX) and gemifloxacin (GFX) by CLSI broth microdilution. Topoisomerase gene (grlA, grlB, gyrA & gyrB) quinolone resistance determining regions (QRDRs) were amplified and sequenced and the effect of reserpine (RES, 20 mg/L) on MIC (i.e. the role of FQ efflux) was evaluated to determine mechanism(s) of resistance.
Results: MIC, QRDR and efflux data are shown in the table. Most FQR SA possessed combined GrlA (S80F)GyrA (S84L) changes. Others had additional changes in GrlA, GyrA or GrlB, but none were found in GyrB. The effect of RES on CFX MIC was variable, but this did not affect FQ MIC as much as QRDR changes. Other FQ were less affected by RES than CFX. NXL101 MIC ranged from 0.03 to 1 mg/L (mode 0.06/0.12 mg/L) and was not affected by any QRDR changes. Some RES effect was observed with NXL101, but most FQR SA had similar NXL101 MIC to the Cont strain (for which NXL101 MIC was not affected by RES).
Conclusion: NXL101 retained activity against highly FQR SA exhibiting a range of QRDR mutations and CFX efflux. NXL101 must target topoisomerases in a manner distinct to that of FQs.
|Session name:||European Society of Clinical Microbiology and Infectious Diseases|
|Location:||ICC, Munich, Germany|
|Back to top|